Galectin Therapeutics Inc. (GALT)

Market Cap	176.67M
Revenue (ttm)	n/a
Net Income (ttm)	-45.23M
Shares Out	62.76M
EPS (ttm)	-0.73
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	130,993
Open	2.750
Previous Close	2.755
Day's Range	2.670 - 2.820
52-Week Range	1.560 - 4.270
Beta	0.63
Analysts	Strong Buy
Price Target	11.00 (+290.76%)
Earnings Date	Nov 13, 2024

About GALT

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 14
• Stock Exchange: NASDAQ
• Ticker Symbol: GALT
• Website: https://galectintherapeutics.com

Analyst Forecast

According to one analyst, the rating for GALT stock is "Strong Buy" and the 12-month stock price forecast is $11.0.

Price Target

$11.0

(290.76% upside)

Analyst Consensus: Strong Buy